ATR-258

Phase 2Small molecule

AAtrogi AB

ATR-258 is one of 10 small molecule programs targeting CLE. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

CLENot yet recruiting

CLEPhase 2

Not yet recruiting

Competition

Competitive Landscape

14 competitors in CLE

#DrugCompanyPhaseTrials

Zytiga

Johnson & Johnson

Phase 3

1 2

Zuragard

ZZurex Pharma, Inc.

Phase 2

1 3

Keto Acid

UUniversity Hospital, Clermont-Ferrand

Phase 3

1 4

Brethine

Sanofi

Preclinical

2 5

ATR-258

AAtrogi AB

Phase 2

1 6

Povidine-Iodine

MMidAtlantic Retina

Phase 2

1 7

Pharmacokinetics

Pfizer

Phase 1

1 8

Clenbuterol

UUniversity of Copenhagen

Preclinical

1 9

Triptorelin Acetate

Ipsen

Preclinical

1 10

Recombinant Hcg

UUniversitair Ziekenhuis Brussel

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Not yet recruiting

CLE

NCT07421024

Clinical

Trials by Indication[1]

Trial2 trials

First-in-human Single and Multiple Dose Trial of ATR-258

Completed·AAtrogi AB·Phase 1·NCT05409924·71 enrolled

The Attractive 2 Trial - Pharmacokinetics of ATR-258 Oral Capsule vs. Oral Solution Formulations in Healthy Volunteers

Completed·AAtrogi AB·Phase 1·NCT06432673·21 enrolled

CLE1 trial

Biased GRK Signaling Via β2-Adrenergic Receptors in Human Skeletal Muscle

Not yet recruiting·MMorten Hostrup, PhD·Phase 2·NCT07421024·10 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for ATR-258. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ATR-258 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ATR-258. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Atrogi AB company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: AAtrogi AB

ATR-258

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Trial2 trials

CLE1 trial

References

Drug Info

Quick Facts

Related News